Avicanna earnings date
Avicanna (0NN) Q3 2026 Earnings Report
DE:0NN Q3 2026 EPS Results
- Actual EPS
- EUR 0.00
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- -EUR 0.01
DE:0NN Q3 2026 Revenue Results
- Actual Revenue
- EUR 3.64M
- Expected Revenue
- ―
- Beat/Miss
- ―
- YoY Revenue Growth
- -10.42%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/12/2026
- Time
- Before Open
- Conference Call
- Thursday, November 12, 2026
Avicanna's next earnings date is estimated for April 6, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was broadly positive. Management highlighted the first positive adjusted EBITDA quarter, improving operating results, stronger gross margins year-over-year, reduced expenses, improved working capital, growth in proprietary and international revenue, the launch and expansion of the QUIX portfolio, and progress in clinical, pharmaceutical, and international initiatives. These positives were tempered by a 10% year-over-year revenue decline, lower gross profit, sequential gross-margin compression, negative operating cash flow, the impact of Veterans Affairs Canada reimbursement changes, licensing revenue variability, debt obligations, and the company's low market valuation.
For Q4, management expects to continue the cost discipline, launch further QUIX SKUs across the Canadian market, improve the MyMedi percentage of sales, and generate “some early signals of international revenue growth”; it expects the majority of recent G&A savings to be recurring into Q4 and going into next year, expects to file an SR&ED claim every year going forward, and expects the Avicanna share of MyMedi sales to trend towards “40% to even 50% of the sales.” Management expects further SKU launches, margin efficiencies, and signals of growth going into Q4, early signals from SMGH this year and next year, significant pharmaceutical milestones going into 2027, and U.S. rescheduling “towards the end of this year or early next year.”
- Ten-Year Milestone and Expanded Business PlatformAvicanna will reach its 10-year anniversary next week. The company has evolved into an international biopharmaceutical company with 68 commercial SKUs, 1 pharmaceutical product, several clinical programs, and established international commercial operations.
- Adjusted EBITDA Turned PositiveAdjusted EBITDA was positive at $222,000 in Q3 2026, improving by $1 million year-over-year and $577,000 from Q2 2026. Management attributed the improvement to stronger margins and lower G&A expenses, including the SR&ED credit.
- Revenue Stabilized SequentiallyQ3 revenue was $5.7 million, down 10% from Q3 2025 but up 2% sequentially from Q2 2026. Management said the sequential increase was an encouraging sign that MyMedi revenue had stabilized following the Veterans Affairs Canada reimbursement changes.
- Proprietary Products and International Revenue GrowthProprietary products and portfolio expansion across retail and medical B2B channels generated 4% year-over-year growth. International revenue increased 21% year-over-year, led by flower and API sales from majority-owned subsidiary SMGH, which achieved its highest API and flower quarterly revenue to date.
- Gross Margin Improvement Year-over-YearGross profit was $2.9 million, while gross margin improved from 49% to 51% year-over-year. Year-to-date gross margin was 55%, up from 52% in the same period last year, driven largely by the increased contribution of Avicanna's proprietary products on MyMedi.
- Strong Growth in MyMedi Proprietary Product MixAvicanna's proprietary products increased from 19% of MyMedi platform sales in Q3 2025 to 31% by the end of Q3 2026. Management said the increase was achieved while MyMedi continued to carry approximately 230 SKUs and 50 to 60 brands.
- Significant G&A and Operating Expense ReductionG&A expenses declined by $1 million, or 27%, year-over-year, and by $777,000 from Q2 2026. Total operating expenses decreased 30% year-over-year, supported by lower professional fees, automation-related human resource reductions, lower clinical education costs, and lower insurance and IT costs.
- Operating Loss and Net Loss NarrowedOperating loss improved by $1.1 million, or 18%, year-over-year, and by $790,000, or 74%, from Q2 2026. Net loss before tax narrowed to $301,000 from $1.4 million in Q3 2025.
- Improved Working Capital PositionNet working capital improved to a surplus of $114,000 from a deficit of $276,000 at the end of Q2 and a deficit of $1.3 million at the end of 2025. Accounts payable and accrued liabilities decreased by $1.4 million, or 16%, as the company used available capital to reduce payables.
- Additional Capital Raised Without Immediate Equity DilutionOn October 29, the company closed a non-brokered private placement of debenture units for gross proceeds of $2 million. The debentures carry a 13% annual interest rate and mature in 1 year, with warrants exercisable at $0.20 per share. Management said the proceeds will be used for working capital and general corporate purposes.
- QUIX Nanotechnology Portfolio LaunchAvicanna launched the initial QUIX portfolio toward the end of Q3, beginning with gummy and capsule SKUs. The proprietary nanoemulsion technology is designed to provide rapid onset and enhanced absorption, with products designed for onset within a 15- to 20-minute window compared with the typical 1.5-hour to 2-hour onset for oral edible products.
- QUIX Portfolio Expansion and Commercial InterestThe QUIX portfolio had expanded to approximately 33 SKUs, including nano drops, Rapid Act Capsules, day-night capsule versions, and gummy multipacks. Management reported commercial listings and interest from Ontario, Alberta, and British Columbia, as well as competing medical channels.
- MyMedi Efficiency and Patient SatisfactionMyMedi implemented lower costs, increased automation and AI, and more efficient patient documentation processes. A survey of 1,500 patients showed satisfaction rates of 90% or above, and management reported record retention rates.
- Integrated Healthcare Program ExpansionAvicanna activated pilot programs with 3 institutional partners to integrate medical cannabis into pain institutions, sleep institutions, hospitals, and other healthcare settings. The program embeds medical documentation into existing electronic medical records and uses pharmacist-led patient support and treatment planning.
- Clinical and Pharmaceutical Pipeline ProgressThe company is advancing a Phase II pilot study with UHN, preparing a Phase I dose-finding escalation study at the University of Calgary, supporting additional preclinical projects, and participating in a real-world evidence study published in the Canadian Journal of Pain. SEDDS capsules similar to the QUIX technology are enrolled in the University of Calgary Phase I study and a Phase II osteoarthritic pain study, with early results expected next year.
- Non-Dilutive R&D Support and Intellectual Property DevelopmentThe company said much of its clinical work is supported by Canadian grants and that its R&D activities are eligible for the SR&ED program, which reimburses 30% of research and development expenditures. Avicanna received approximately $330,000 to $348,000 in SR&ED credit and expects to file a claim every year going forward, barring changes in legislation.
- Manufacturing and Margin Improvement InitiativesAvicanna plans to consolidate its Canadian manufacturing relationships, previously totaling 10 manufacturing partners, to improve margins. Management also cited potential economies of scale and more strategic manufacturer selection as additional sources of future margin improvement.
- International Expansion and Strategic Partnership OpportunitiesThe company is pursuing strategic partnerships in England, Australia, Brazil, and potentially the United States to expand its scientific platform, products, patient support, and medical affairs capabilities. Management also reported interest in QUIX, other intellectual property, the MyMedi platform, Trunerox, and the pharmaceutical pipeline from international companies and countries.
- Canadian Government Trade SupportGlobal Affairs Canada and the Trade Commissioner's office are supporting Avicanna and certain industry peers with international expansion efforts. Management described this as a positive signal and validation of the company's maturity and the Canadian cannabinoid industry.
- Potential M&A and U.S. OpportunityAvicanna is assessing tuck-in merger and acquisition opportunities that could add revenue and market opportunity. Management also said it expects U.S. rescheduling to take place toward the end of this year or early next year and believes the company's products and platform have an opportunity in the United States.
DE:0NN Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Apr 06, 2027 | 2026 (Q4) | ―- | 0 | ― | ― |
| Nov 12, 2026 | 2026 (Q3) | ―-0.00 | -0.01 | 91.67% (+0.01) | |
| Aug 14, 2026 | 2026 (Q2) | ―-0.01 | 0 | -14.29% (-0.00) | |
| May 14, 2026 | 2026 (Q1) | ―- | 0 | ― | |
| Apr 01, 2026 | 2025 (Q4) | ―-0.00 | 0 | -350.00% (-0.00) | |
| Nov 14, 2025 | 2025 (Q3) | ―-0.01 | -0.01 | -33.33% (-0.00) | |
| Aug 13, 2025 | 2025 (Q2) | ―-0.00 | -0.01 | 63.16% (+0.01) | |
| May 14, 2025 | 2025 (Q1) | ―- | -0.01 | ― | |
| Mar 31, 2025 | 2024 (Q4) | ―0.00 | -0.02 | 100.00% (+0.02) | |
| Nov 14, 2024 | 2024 (Q3) | ―-0.01 | -0.01 | 35.71% (+0.00) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

